Antipsychotic medications may result in increased risk of gestational diabetes

0

An increasing number of women are treated with antipsychotic drugs during pregnancy even though safety questions remain unanswered. Certain antipsychotic drugs used to treat bipolar disorder, schizophrenia, and other severe mental health disorders have previously been shown to have metabolic side effects, including weight gain and diabetes, in the general population. Whether the continued use of such antipsychotic medications during pregnancy may lead to an increased risk of gestational diabetes was not known.

Researchers from Brigham and Women's Hospital, Harvard Medical School, Harvard School of Public Health and Massachusetts General Hospital addressed the link between antipsychotic treatment during pregnancy and gestational diabetes in a new research paper published online today by the American Journal of Psychiatry.

Quantifying this risk was important, as approximately 50 percent of women who have gestational diabetes will develop type 2 diabetes in the years following pregnancy. Gestational diabetes is also associated with adverse pregnancy outcomes, including preeclampsia, cesarean delivery, neonatal hypoglycemia, and macrosomia.

The study examined the risk of developing gestational diabetes associated with continued use of several antipsychotic medications during pregnancy. The researchers focused on five atypical antipsychotics: aripiprazole, ziprasidone, quetiapine, risperidone, and olanzapine. Continuation of olanzapine and quetiapine showed an increased risk for gestational diabetes compared with women who discontinued these medications. Aripiprazole, ziprasidone, and risperidone during pregnancy was not associated with an increased risk of gestational diabetes. The study included women without pre-existing diabetes who received antipsychotic drugs during the three months before pregnancy, and compared women who continued to take medication during the first half of pregnancy to those who stopped during pregnancy.

"The risks of gestational diabetes observed during pregnancy are in line with expectations based on the metabolic side effects observed in the general population," said senior author Krista F. Huybrechts, MS, PhD, an epidemiologist in the Division of Pharmacoepidemiology and Pharmacoeconomics at BWH. "Certain antipsychotics have different levels of risk of metabolic side effects."

Continuation of quetiapine led to a 28 percent increased risk, corresponding to 1.6 extra cases of gestational diabetes per 100 women treated. Continuation of olanzapine led to a 61 percent increased risk, corresponding to 4.4 extra cases of gestational diabetes per 100 women treated. The study accounted for a broad range of proxy variables. Researchers are confident that increased risks are not due to confounding by incomplete overweight or obesity measurements at the start of pregnancy.

"Clinicians must weigh the benefits of staying on a stable regimen against the risks of continuing treatment with a higher-risk atypical antipsychotic during pregnancy to make an informed decision about the best course of treatment for the patient in question," said Huybrechts.

###

This study was supported by funding from the National Institute of Mental Health.

Paper cited: Yoonyoung Park, ScD et al. "Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes" American Journal of Psychiatry DOI: 10.1176/appi.ajp.2018.17040393

Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 4.2 million annual patient visits and nearly 46,000 inpatient stays, is the largest birthing center in Massachusetts and employs nearly 16,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Brigham Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 3,000 researchers, including physician-investigators and renowned biomedical scientists and faculty supported by nearly $666 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative as well as the TIMI Study Group, one of the premier cardiovascular clinical trials groups. For more information, resources and to follow us on social media, please visit BWH's online newsroom.

Media Contact

Elaine St. Peter
[email protected]
617-525-6375
@BrighamWomens

http://www.brighamandwomens.org

http://dx.doi.org/10.1176/appi.ajp.2018.17040393

Leave a Reply

%d bloggers like this: